Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
| Revenue: $0M |
| Revenue Growth (YOY): nan% |
| Profit (% of Rev): nan% |
| Income (% of Rev): -inf% |
| Income Growth (YOY): 155.74% |
| Operating Income: $-15M |
| Operating Cash Flow: $-12M |
| Operating Cash Flow Growth (YoY): 112.91% |
| Annual Dividend Yield: 0.00% |
| Total Assets: $121M |
| Total Liabilities: $75M |
| Cash & Equivalent: $16M |
| Total Debt: $23M |
| Debt/Equity: 0.50 |
| Quick Ratio: 6.12 |
| Current Ratio: 6.12 |
| Price/Book: 6.64 |
| Price/Earnings: -2.51 |
| EBITDA: $-15M |
| EPS: -0.63 |
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Sell.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.